FTC sues to block $28B Amgen-Horizon deal, in move that will send shockwaves through biopharma M&A
The FTC on Tuesday filed a lawsuit to block Amgen’s proposed $28 billion buyout of Horizon Therapeutics, a move that Wall Street analysts have warned could dull M&A enthusiasm across the sector.
The agency argued that the merger would allow Amgen to use rebates on its existing drugs to “pressure insurance companies and pharmacy benefit managers into favoring” Horizon’s thyroid eye disease and chronic refractory gout products: Tepezza and Krystexxa, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
